Copyright
©The Author(s) 2015.
World J Gastroenterol. Sep 28, 2015; 21(36): 10435-10442
Published online Sep 28, 2015. doi: 10.3748/wjg.v21.i36.10435
Published online Sep 28, 2015. doi: 10.3748/wjg.v21.i36.10435
Table 1 Demographic distribution of the subjects receiving different eradication regimens
Characteristic | Hybrid therapy (n = 88) | Sequential therapy (n = 87) | P value |
Age (mean ± SD), yr | 52.1 ± 13.0 | 54.6 ± 13.2 | 0.26 |
Gender (male/female) | 39/49 | 25/62 | 0.04 |
Smoking | 14 | 6 | 0.10 |
Alcohol consumption | 20 | 18 | 0.74 |
Ingestion of coffee | 61 | 57 | 0.59 |
NSAID user | 8 | 8 | 0.96 |
Underlying diseases | 26 | 23 | 0.77 |
Endoscopic finding (Peptic ulcer/non-ulcer dyspepsia) | 46/42 | 32/55 | 0.06 |
Helicobacter pylori density (mild/moderate/marked) | 8/42/38 | 4/57/26 | 0.26 |
Table 2 Outcomes of sequential and hybrid therapy
Variable | Hybrid therapy | Sequential therapy | P value | ||||
Patients | Eradication rate | 95%CI | Patients | Eradication rate | 95%CI | ||
Intension-to-treat analysis | 88 | 92.0% | 86.4-97.7 | 87 | 78.2% | 69.5-86.8 | 0.01 |
Per-protocol analysis | 84 | 96.4% | 92.5-100.4 | 83 | 81.9% | 73.6-90.2 | 0.01 |
Table 3 Adverse events during treatment
Hybrid therapy | Sequential therapy | P value | |
Compliance, n (%) | 84 (97.7) | 83 (97.6) | 0.99 |
Side effects, n (%) | 52 (59) | 60 (69) | 0.22 |
Diarrhea | 16/1/11 | 15/0/0 | 0.42 |
Constipation | 1/0/0 | 2/0/0 | 0.50 |
Anorexia | 0 | 1/0/0 | 0.70 |
Nausea | 4/1/0 | 9/0/1 | 0.92 |
Vomiting | 5/2/0 | 3/1/0 | 0.57 |
Abdominal pain | 5/0/0 | 9/0/0 | 0.87 |
Skin rash | 3/2/0 | 1/2/0 | 0.74 |
Headache | 9/1/1 | 16/1/1 | 0.41 |
Dizziness | 6/1/0 | 9/0/0 | 0.70 |
Bitter taste | 25/6/0 | 36/3/0 | 0.17 |
Fatigue | 3/0/0 | 4/0/0 | 0.30 |
Table 4 Univariate analysis of the clinical factors influencing the efficacy of eradication therapy n (%)
Variable | Sequential therapy | P value | Hybrid therapy | P value |
Resistance (n = 124) | n = 59 | n = 65 | ||
Metronidazole | 0.22 | 0.74 | ||
Susceptible | 32 (84.2) | 37 (94.9) | ||
Resistant | 14 (66.7) | 25 (96.1) | ||
Clarithromycin | 0.73 | 0.51 | ||
Susceptible | 37 (77.1) | 54 (94.7) | ||
Resistant | 9 (81.8) | 8 (100) | ||
Tetracycline | 0.59 | NA | ||
Susceptible | 45 (77.6) | 62 (95.4) | ||
Resistant | 1 (100) | |||
Levofloxacin | 0.46 | 0.45 | ||
Susceptible | 36 (75.0) | 52 (94.5) | ||
Resistant | 10 (90.9) | 10 (100) | ||
Amoxicillin | NA | NA | ||
Susceptible | 46 (78.0) | 62 (95.4) | ||
Resistant | ||||
Dual resistance | 0.66 | 0.65 | ||
Present | 5 (71.4) | 4 (100) | ||
Absent | 41 (78.8) | 58 (95.0) | ||
Compliance | 0.47 | 0.66 | ||
Good | 66 (79.5) | 78 (94.0) | ||
Poor | 2 (100) | 3 (100) | ||
Smoking | 0.2 | 0.31 | ||
Present | 6 (100) | 14 (100) | ||
Absent | 62 (78.5) | 67 (93.1) | ||
Alcohol | 0.29 | 0.21 | ||
Present | 16 (88.9) | 20 (100) | ||
Absent | 52 (77.6) | 61 (92.4) | ||
Gastroduodenal disease | 0.91 | 0.57 | ||
Non-ulcer dyspepsia | 43 (79.6) | 38 (92.7) | ||
Peptic ulcer | 25 (80.6) | 43 (95.6) | ||
Bacterial density | 0.31 | 0.4 | ||
Mild | 4 (100) | 7 (87.5) | ||
Moderate/marked | 64 (79.0) | 74 (94.9) |
-
Citation: Chen KY, Lin TJ, Lin CL, Lee HC, Wang CK, Wu DC. Hybrid
vs sequential therapy for eradication ofHelicobacter pylori in Taiwan: A prospective randomized trial. World J Gastroenterol 2015; 21(36): 10435-10442 - URL: https://www.wjgnet.com/1007-9327/full/v21/i36/10435.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i36.10435